BIOXYNE LIMITED — Capital/Financing Update 2017

May 25, 2017

==> picture [596 x 109] intentionally omitted <==

----- Start of picture text ----- Suite 506, Level 5, 50 Clarence StSydney NSW 2000P: +61 2 9078 8180W: www.bioxyne.com----- End of picture text -----

ASX Announcement 26 May 2017

Rights Issue Closes

• Shareholders subscribed for 157,033,283 shares offered in the rights issue raising $1,570,333, before costs

• Underwriters will subscribe for the remaining 96,749,342 shares for a balance of $967,493, before costs

Bioxyne Limited (ASX: BXN) is pleased to announce that the recent fully underwritten nonrenounceable rights issue has closed with 61.9% of the rights shares being subscribed for by shareholders, with the balance being taken up by the underwriters.

Accordingly the Company will issue to shareholders 253,782,625 ordinary shares to raise $2,537,826 (before costs).

The securities above are to be issued on 30 May 2017.

A summary of the results of the rights issue and shares currently on issue is set out in the table below:

	Number of Shares	Subscription Funds($)
Application for entitlement shares	157,033,283	1,570,333
Shares taken up by underwriters	96,749,342	967,493
Total applications	253,782,625	2,537,826

Event	Number of Shares
Shares Currently on Issue	253,782,625
Entitlement Shares taken up under the rights issue	157,033,283
Shares taken up by the underwriter	96,749,342
Rights Issue Shares	253,782,625
Total shares after rights issue	507,565,250

Guy Robertson Company Secretary

About Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian life sciences and health products company with a focus on immune health and immunotherapeutic products.

Through our recent acquisition in New Zealand, now trading as Bioxyne International, we are further developing a range of existing functional foods and beauty products containing ingredients sourced exclusively from New Zealand, for our direct sales channel.

Bioxyne has a strategic investment in the consumer dietary supplements and functional foods markets through its proprietary probiotic, Lactobacillus fermentum PCC®. Bioxyne is a company creating value for consumers and investors by delivering safe and effective solutions.

Bioxyne’s focus is currently on the company’s probiotic business and proprietary product Lactobacillus fermentum PCC® which is supported by a manufacturing and distribution agreement with Chr. Hansen (Denmark) a global leader in the manufacturing of natural food additives and supplements products for the food, health, pharmaceutical and agriculture industries.

Bioxyne also has a distribution agreement with Nu-Skin Enterprises (USA) a successful worldwide multilevel marketing company who pride themselves in offering only quality solutions to their customers.

Tony Ho Guy Robertson Non-executive Chairman Chief Operating Officer Mob: +61 417 345 839 Mob: +61 407 983 270